Torrent Pharmaceuticals' net profit declined by 10% year-on-year (YoY) to ₹534 crore in the second quarter (Q2) of fiscal year 2027 (FY27). Despite this drop, the company's revenue from the United States surged by 24%, contributing to a significant overall revenue increase. The total revenue from operations rose sharply by 50.78% YoY to ₹4,979 crore during the quarter ending September 30, 2026.
- Net profit fell 10% YoY to ₹534 crore in Q2 FY27.
- Total revenue increased 50.78% YoY to ₹4,979 crore.
- US revenue grew 24% YoY to ₹417 crore.
- Brazil revenue rose 38% YoY to ₹440 crore.
- Germany revenue declined 7% YoY to ₹283 crore.
- India revenue increased 20% YoY to ₹2,181 crore.
- EBITDA margin expanded by 70 basis points to 33.5%.
What caused the decline in Torrent Pharma's net profit?
Torrent Pharmaceuticals posted a consolidated net profit of ₹534 crore for Q2 FY27, down from ₹591 crore in the same period last year. The decline was influenced by higher total expenses, which rose to ₹4,222 crore from ₹2,471 crore in Q2 FY26. Increased costs affected the overall profitability despite strong revenue growth.
How did Torrent Pharma's revenue perform in different markets?
The company's total revenue from operations increased significantly by 50.78% YoY to ₹4,979 crore in Q2 FY27. Key market performances include:
- India: Revenue rose 20% YoY to ₹2,181 crore.
- United States: Revenue surged 24% YoY to ₹417 crore.
- Brazil: Revenue increased 38% YoY to ₹440 crore.
- Germany: Revenue declined 7% YoY to ₹283 crore.
What changes occurred in Torrent Pharma's operational earnings?
Operational earnings before interest, tax, depreciation, and amortisation (EBITDA) grew 53.8% YoY to ₹1,666 crore in Q2 FY27, compared to ₹1,083 crore in Q2 FY26. The EBITDA margin improved by 70 basis points to 33.5%, up from 32.8% in the previous year, indicating better operational efficiency.
How did Torrent Pharma perform in the first half of FY27?
For the six months ending September 30, 2026 (H1 FY27), Torrent Pharmaceuticals reported a consolidated net profit of ₹1,100 crore. This figure represents a 3.42% decrease compared to ₹1,139 crore in the same period of the previous fiscal year.
What was the stock market reaction to Torrent Pharma's Q2 results?
Shares of Torrent Pharmaceuticals closed 1.97% lower at ₹4,524.40 on the National Stock Exchange (NSE) on October 23, 2026, the day the results were announced after market hours. Over the past week, the stock declined by 1%, and over the last month, it fell by 9%. However, the stock has gained more than 17% year-to-date.
The stock reached a 52-week high of ₹5,250 on August 3, 2026, and a 52-week low of ₹3,532.60 on November 6, 2026. As of October 23, 2026, Torrent Pharmaceuticals had a market capitalisation of ₹1.72 lakh crore.
Frequently Asked Questions
Q: What was Torrent Pharma's net profit in Q2 FY27?
A: The net profit was ₹534 crore, a 10% decrease compared to the previous year.
Q: Which market showed the highest revenue growth for Torrent Pharma?
A: Brazil showed the highest revenue growth with a 38% increase to ₹440 crore.
Q: How did the EBITDA margin change in Q2 FY27?
A: The EBITDA margin expanded by 70 basis points to 33.5% from 32.8% in the previous year.
